Stocks · News reference

Hemab Therapeutics to Host Third Quarter 2026 Financial Results Conference Call

2026-11-03 14:02:15 UTC

Hemab Therapeutics has scheduled a conference call for November 10, 2026, to discuss its financial results and provide a corporate update for the third quarter ended September 30, 2026.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

COAG

Source: fiscal.ai
Observed: 2026-11-03 14:02:15 UTC
Checked: 2026-11-03 14:03:20 UTC
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Fiscal.ai2026-11-04 22:31:57 UTC
Hemab Therapeutics to Present Clinical and Preclinical Data at 68th ASH Annual Meeting
Hemab Therapeutics announced it will present data from multiple pipeline programs at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2026.
COAG
Benzinga2026-11-04 14:13:25 UTCBenzinga Newsdesk
Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting
COAG
Fiscal.ai2026-10-29 13:03:32 UTC
J.P. Morgan and Rodman & Renshaw Initiate Coverage on Hemab Therapeutics Holdings, Inc.
J.P. Morgan and Rodman & Renshaw have initiated research coverage on Hemab Therapeutics Holdings, Inc. with positive ratings and specific price targets.
COAG
Benzinga2026-10-15 17:06:02 UTCBenzinga Newsdesk
Hemab Therapeutics shares are trading higher after JP Morgan initiated its coverage on the stock with an Overweight rating and announced a price target of $70.
COAG
Benzinga2026-10-15 13:14:08 UTCBenzinga Newsdesk
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70
COAG
Benzinga2026-10-12 17:12:43 UTCBenzinga Newsdesk
Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Hemab Therapeutics Hldgs (NASDAQ:COAG) with a Buy rating and announces Price Target of $56.
COAG

Hemab Therapeutics to Host Third Quarter 2026 Financial Results Conference Call

Connected Markets

Related Headlines

Hemab Therapeutics to Present Clinical and Preclinical Data at 68th ASH Annual Meeting

Hemab Therapeutics To Present Two Presentations At American Society Of Hematology Annual Meeting

J.P. Morgan and Rodman & Renshaw Initiate Coverage on Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics shares are trading higher after JP Morgan initiated its coverage on the stock with an Overweight rating and announced a price target of $70.

JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70

Rodman & Renshaw Initiates Coverage On Hemab Therapeutics Hldgs with Buy Rating, Announces Price Target of $56